{"product_id":"ango-vrio-analysis","title":"AngioDynamics, Inc. (ANGO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the core of what makes AngioDynamics, Inc. (ANGO) a true market contender! Our VRIO analysis cuts straight to the heart of its competitive edge, examining the Value, Rarity, Inimitability, and Organization of its key resources. \u0026amp;O4\u0026amp; reveals the critical insights - will this foundation secure sustained success or expose a vulnerability? Dive in below to uncover the full strategic breakdown and what it means for the future of AngioDynamics, Inc. (ANGO).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAngioDynamics, Inc. (ANGO) - VRIO Analysis: 1. Focused Med Tech Product Portfolio (Auryon, AlphaVac, NanoKnife)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at AngioDynamics, Inc. (ANGO) now that they’ve shed the slower legacy businesses. The focus is squarely on the Med Tech segment, and the numbers from fiscal year 2025 show that focus is paying off with real growth.\u003c\/p\u003e\n\n\u003cp\u003eThe takeaway is this: the portfolio is currently valuable and somewhat rare, but the competitive moat isn't deep enough to last forever without more innovation.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Accelerating Med Tech Growth\u003c\/h3\u003e\n\u003cp\u003eThis portfolio is definitely driving value by accelerating revenue. For the full fiscal year 2025, Med Tech net sales hit \u003cstrong\u003e$126.7 million\u003c\/strong\u003e, which is a solid \u003cstrong\u003e19.5%\u003c\/strong\u003e increase year-over-year. This segment is the engine now, especially when you look at the fourth quarter performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAuryon sales: \u003cstrong\u003e$15.6 million\u003c\/strong\u003e (up \u003cstrong\u003e19.7%\u003c\/strong\u003e in Q4 FY2025).\u003c\/li\u003e\n\u003cli\u003eMechanical Thrombectomy (AlphaVac\/AngioVac): \u003cstrong\u003e$11.3 million\u003c\/strong\u003e (up a huge \u003cstrong\u003e44.7%\u003c\/strong\u003e in Q4 FY2025).\u003c\/li\u003e\n\u003cli\u003eNanoKnife disposables: \u003cstrong\u003e$5.7 million\u003c\/strong\u003e (up \u003cstrong\u003e5.5%\u003c\/strong\u003e in Q4 FY2025).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis growth shows strong market acceptance for these specific, high-value procedures. It’s a clear win for the current strategy.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: A Unique Combination of Technologies\u003c\/h3\u003e\n\u003cp\u003eThe rarity here isn't just having one good product; it’s the specific combination of three distinct, advanced platforms under one roof. Auryon is rare because it’s a pioneering laser atherectomy device capable of treating lesions of any type, length, or location, above or below the knee, while minimizing vessel wall impact. NanoKnife is also unique as the first and only non-thermal, radiation-free ablation technology using irreversible electroporation (IRE) for prostate treatment, which preserves surrounding structures.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the IP foundation:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Platform\u003c\/td\u003e\n\u003ctd\u003eKey Differentiating Feature\u003c\/td\u003e\n\u003ctd\u003ePatent Status (US)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuryon\u003c\/td\u003e\n\u003ctd\u003e355nm laser for all lesion types\u003c\/td\u003e\n\u003ctd\u003eMultiple active patents listed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanoKnife\u003c\/td\u003e\n\u003ctd\u003eNon-thermal IRE ablation\u003c\/td\u003e\n\u003ctd\u003eCPT Category I Code secured for prostate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlphaVac\/AngioVac\u003c\/td\u003e\n\u003ctd\u003eMechanical thrombectomy systems\u003c\/td\u003e\n\u003ctd\u003eMultiple design patents listed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eImitability: Protected, But Not Impenetrable\u003c\/h3\u003e\n\u003cp\u003eImitability is high, but not immediately. The core devices are protected by numerous U.S. patents, which makes direct copying difficult and expensive. However, the competitive landscape is tough. Major players like Medtronic and Boston Scientific have massive R\u0026amp;D budgets and established distribution networks, and they are actively developing competing endovascular solutions. What’s harder to copy quickly is the commercial execution and the clinical data AngioDynamics is building, like the ongoing AMBITION BTK study for Auryon. Still, sustained protection relies on continuous, rapid innovation.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Clear Strategic Alignment\u003c\/h3\u003e\n\u003cp\u003eThe organization scores high here because management has been ruthless in focusing resources. They divested legacy businesses like Dialysis, BioSentry, and PICC\/Midline portfolios to fund and concentrate entirely on this Med Tech segment. Furthermore, they are organizing to capture future revenue through regulatory wins; securing the CPT Category I Code for NanoKnife IRE treatment of pancreatic lesions, effective January 1, 2027, shows forward-looking operational planning. They are structured to push these specific platforms.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary, Based on Momentum\u003c\/h3\u003e\n\u003cp\u003eRight now, the focused portfolio provides a \u003cstrong\u003etemporary competitive advantage\u003c\/strong\u003e. The combination of a unique laser atherectomy, a non-thermal ablation tool, and high-growth thrombectomy systems is powerful, as seen in the \u003cstrong\u003e19.5%\u003c\/strong\u003e Med Tech growth for FY2025. What this estimate hides, though, is that the advantage erodes as competitors launch their own next-generation devices. The advantage is sustained only if the next generation of Auryon or NanoKnife is already in the pipeline, ready to launch before a competitor closes the gap.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAngioDynamics, Inc. (ANGO) - VRIO Analysis: 2. NanoKnife Irreversible Electroporation (IRE) Technology \u0026amp; Clinical Data\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Offers a function-preserving treatment option in oncology, addressing a significant clinical need, especially with the new CPT code pathway.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFDA 510(k) clearance for prostate tissue ablation received in late 2024.\u003c\/li\u003e\n\u003cli\u003ePRESERVE trial primary endpoint met: 84.0% of men free from in-field, clinically significant disease at 12 months post-procedure.\u003c\/li\u003e\n\u003cli\u003eUrinary continence preserved at 95.4% at 12 months post-procedure in the PRESERVE study.\u003c\/li\u003e\n\u003cli\u003eBaseline erectile function sufficient for intercourse maintained at 84% at 12 months post-procedure in the PRESERVE study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. IRE is a distinct mechanism compared to thermal ablation, making the core technology itself somewhat rare in the market.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe technology is non-thermal, creating permanent nanopores via high-voltage pulses.\u003c\/li\u003e\n\u003cli\u003eFindings reinforce data from over 32 clinical studies involving over 2,600 patients worldwide.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. The underlying science is known, but the specific system design and accumulated clinical data are difficult to replicate.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe PRESERVE pivotal study enrolled 121 patients across 17 clinical sites in the United States.\u003c\/li\u003e\n\u003cli\u003eThe system itself costs doctors approximately $375,000.\u003c\/li\u003e\n\u003cli\u003eDisposable electrodes, which are used in each treatment, cost several thousand dollars each.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. They secured key regulatory\/reimbursement wins (like the pancreas CPT code), showing organizational focus on adoption.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCategory I CPT® codes for IRE in prostate and liver lesions granted by the AMA, effective January 1, 2026.\u003c\/li\u003e\n\u003cli\u003eFor the three months ended November 30, NanoKnife accounted for $6 million in sales, with $5 million from disposable electrodes.\u003c\/li\u003e\n\u003cli\u003eNanoKnife disposable sales in Q4 Fiscal Year 2024 were $5.4 million, an 18.0% increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eANGO lost $184 million during its fiscal year 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Deep clinical data and established reimbursement pathways create a high barrier for new, unproven competitors in this niche.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRESERVE Study Patients\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e121\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePivotal trial for prostate indication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncologic Success Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e84.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFree from clinically significant disease at 12 months post-procedure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrinary Continence Preservation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e95.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAt 12 months post-procedure (short-term)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanoKnife Disposable Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 Fiscal Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanoKnife Disposable Sales Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year for Q4 Fiscal Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed Tech Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter ended August 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPT Category I Codes Effective Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 1, 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor prostate and liver IRE procedures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eAngioDynamics, Inc. (ANGO) - VRIO Analysis: 3. Strategic Portfolio Simplification Success\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Shedding lower-margin, slow-growth assets (like PICC\/Midline) improved overall gross margin to \u003cstrong\u003e53.9% GAAP for FY2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Many companies divest assets, but AngioDynamics executed a deep, multi-year overhaul, which is organizationally rare.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The act is imitable, but the successful completion after years of work is not easily copied by a competitor starting today.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. This required significant management discipline, legal work (settling old suits), and operational restructuring.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement discipline supported the repurchase program authorizing up to \u003cstrong\u003e$15.0 million\u003c\/strong\u003e of outstanding common shares.\u003c\/li\u003e\n\u003cli\u003eOperational restructuring included eliminating certain sales, marketing, and operational expenses following the divestitures.\u003c\/li\u003e\n\u003cli\u003eThe company had \u003cstrong\u003eno long-term debt\u003c\/strong\u003e after repaying all amounts outstanding under its credit agreement in the first fiscal quarter of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The act is imitable, but the successful completion after years of work is not easily copied by a competitor starting today.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. This required significant management discipline, legal work (settling old suits), and operational restructuring.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The benefit is realized now; the advantage shifts to what they build with the freed-up capital and focus.\u003c\/p\u003e\n\u003cp\u003eThe portfolio simplification involved the divestiture of the PICC and Midline product portfolios in \u003cstrong\u003eFebruary 2024\u003c\/strong\u003e, along with the discontinuation of RadioFrequency and Syntrax products.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDivested\/Discontinued Portfolio Data (FY2023)\u003c\/th\u003e\n\u003cth\u003eTransaction Value\/Impact\u003c\/th\u003e\n\u003cth\u003ePost-Simplification Result (FY2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePICC\/Midline Annual Sales\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$43.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSale value up to \u003cstrong\u003e$45 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A (Removed from results)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRF\/Syntrax Annual Sales\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$5.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDiscontinued\u003c\/td\u003e\n\u003ctd\u003eN\/A (Removed from results)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue Reduction (FY2024 Est.)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$50 million\u003c\/strong\u003e reduction\u003c\/td\u003e\n\u003ctd\u003eNet Sales of \u003cstrong\u003e$292.7 million\u003c\/strong\u003e (FY2025 GAAP)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin Impact\u003c\/td\u003e\n\u003ctd\u003eLower Margin Assets\u003c\/td\u003e\n\u003ctd\u003eExpected to be \u003cstrong\u003eaccretive to FY2024 gross margin\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e53.9% GAAP Gross Margin\u003c\/strong\u003e (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eAngioDynamics, Inc. (ANGO) - VRIO Analysis: 4. Positive Adjusted EBITDA Trajectory\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Achieved full-year FY2025 Pro Forma Adjusted EBITDA of \u003cstrong\u003e$7.6 million\u003c\/strong\u003e, signaling a shift to operational profitability from a pro forma adjusted EBITDA loss of \u003cstrong\u003e$(3.2) million\u003c\/strong\u003e in fiscal year 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate. Turning positive adjusted EBITDA while still investing in growth platforms is a key milestone for a transforming company.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low. This is a lagging indicator of past successful cost control and revenue growth, not a resource itself.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High. It shows management successfully controlled costs and scaled the higher-margin Med Tech business effectively.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. It’s a performance metric; sustained advantage requires maintaining this profitability level.\u003c\/p\u003e\n\u003cp\u003eThe trajectory toward positive full-year Adjusted EBITDA in FY2025 involved sequential quarterly improvements:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFiscal Period\u003c\/th\u003e\n\u003cth\u003ePro Forma Adjusted EBITDA (Millions USD)\u003c\/th\u003e\n\u003cth\u003eGAAP Gross Margin (%)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year FY2024\u003c\/td\u003e\n\u003ctd\u003e$(3.2)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 FY2025\u003c\/td\u003e\n\u003ctd\u003e$(0.2)\u003c\/td\u003e\n\u003ctd\u003e54.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 FY2025\u003c\/td\u003e\n\u003ctd\u003e$3.1\u003c\/td\u003e\n\u003ctd\u003e54.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 FY2025\u003c\/td\u003e\n\u003ctd\u003e$3.4\u003c\/td\u003e\n\u003ctd\u003e52.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year FY2025\u003c\/td\u003e\n\u003ctd\u003e$7.6\u003c\/td\u003e\n\u003ctd\u003e53.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 FY2026\u003c\/td\u003e\n\u003ctd\u003e$2.2\u003c\/td\u003e\n\u003ctd\u003e55.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe operational leverage is further evidenced by Med Tech net sales growth across the fiscal year:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMed Tech Net Sales Growth Q1 FY2025: \u003cstrong\u003e8.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMed Tech Net Sales Growth Q2 FY2025: \u003cstrong\u003e25.0%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMed Tech Net Sales Growth Q4 FY2025: \u003cstrong\u003e22.0%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMed Tech Net Sales Growth Q1 FY2026: \u003cstrong\u003e26.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company ended FY2025 with a cash balance of \u003cstrong\u003e$55.9 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAngioDynamics, Inc. (ANGO) - VRIO Analysis: 5. Strong Cash Position and Financial Flexibility\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ended FY2025 with \u003cstrong\u003e$55.9 million\u003c\/strong\u003e in cash and cash equivalents as of May 31, 2025, and a secured revolving credit facility of up to \u003cstrong\u003e$25.0 million\u003c\/strong\u003e. This position provided a buffer against risks such as the reported \u003cstrong\u003e$1.6 million\u003c\/strong\u003e tariff-driven Cost of Goods Sold impact in Q4 FY2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Achieving a cash balance of \u003cstrong\u003e$55.9 million\u003c\/strong\u003e while maintaining a \u003cstrong\u003edebt-free balance sheet\u003c\/strong\u003e at the end of FY2025 is strong for a company of this size. The company subsequently ended Q1 FY2026 with \u003cstrong\u003e$38.8 million\u003c\/strong\u003e in cash and cash equivalents.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. The cash amount itself is fungible; the advantage lies in the strategic deployment and the established financial structure, such as securing the revolver with zero dilution.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management secured the revolving credit facility subsequent to Q3 FY2025 and executed operations to generate \u003cstrong\u003e$16.2 million\u003c\/strong\u003e of free cash flow in Q4 FY2025. The company ended Q1 FY2026 with cash usage ahead of expectations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The advantage is derived from the optionality provided by the liquidity for near-term investment or Mergers \u0026amp; Acquisitions, as cash balances are subject to burn rate and operational performance.\u003c\/p\u003e\n\u003cp\u003eKey Financial Metrics for Cash Position:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$55.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay 31, 2025 (FY2025 End)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevolving Credit Facility\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSecured in FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Status\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eZero Debt\u003c\/strong\u003e \/ Debt-Free\u003c\/td\u003e\n\u003ctd\u003eFY2025 End \/ Q1 FY2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAugust 31, 2025 (Q1 FY2026 End)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Tariff Impact (FY2026)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.0 - $6.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Fiscal Year 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eManagement's execution on financial flexibility is evidenced by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEnding FY2025 with \u003cstrong\u003e$55.9 million\u003c\/strong\u003e in cash, exceeding expectations.\u003c\/li\u003e\n\u003cli\u003eEntering into the revolving credit facility providing up to \u003cstrong\u003e$25.0 million\u003c\/strong\u003e for enhanced flexibility and working capital support at low cost with zero dilution.\u003c\/li\u003e\n\u003cli\u003eMaintaining a commitment to be cash flow positive for the full fiscal year 2026.\u003c\/li\u003e\n\u003cli\u003eAchieving positive Adjusted EBITDA of \u003cstrong\u003e$7.6 million\u003c\/strong\u003e for the full year FY2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAngioDynamics, Inc. (ANGO) - VRIO Analysis: 6. Thrombus Management Platform (AlphaVac and AngioVac)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e These mechanical thrombectomy systems address a large, growing market for clearing dangerous blood clots, contributing to the 19.5% Med Tech growth reported for Fiscal Year 2025. The global Mechanical Thrombectomy Devices Market was valued at $1.51 billion in 2024 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.1% to 7.3% through the forecast periods. The mechanical thrombectomy segment specifically was valued at $969.60 million in 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While thrombectomy devices exist, the specific design and clinical adoption of AngioDynamics' offerings are gaining traction. Key milestones include AlphaVac receiving both FDA 510(k) clearance and CE Marking for the pulmonary embolism indication in fiscal years 2024 and 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Competitors are rapidly innovating in the mechanical thrombectomy space, evidenced by trends such as 61% of newly introduced devices in 2024 featuring hybrid capabilities (aspiration and stent retrieval).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The successful commercial launch of AlphaVac and continued adoption of AngioVac show strong sales execution, as demonstrated by the mechanical thrombectomy franchise (AngioVac\/AlphaVac) revenue increasing 44.7% in the fourth quarter of Fiscal Year 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is a hot area; sustained advantage requires faster iteration than competitors.\u003c\/p\u003e\n\u003cp\u003eThe following table details recent reported sales performance for the individual components of the platform:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePeriod (Fiscal Year)\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eRevenue Amount\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003ctd\u003eAlphaVac\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6.8%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003eAngioVac\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSimilar to prior-year quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003eAlphaVac\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown from $2.0 million in Q3 FY2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003eAngioVac\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7.7%\u003c\/strong\u003e decline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003eAlphaVac\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.8%\u003c\/strong\u003e growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe sequential momentum for AlphaVac was significant in Q4 FY2024, achieving a more than 68% sequential increase in revenue during that quarter. The overall Med Tech segment, which includes the thrombus management platform, saw net sales of $126.7 million for the full Fiscal Year 2025, representing a 19.5% increase from the prior year.\u003c\/p\u003e\n\u003cp\u003eKey organizational and market factors influencing the platform's position include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNorth America accounted for 47% of the total mechanical thrombectomy device utilization in 2024.\u003c\/li\u003e\n\u003cli\u003eThe global Thrombectomy Devices Market is expected to grow by USD 841 million between 2024 and 2029.\u003c\/li\u003e\n\u003cli\u003eAlphaVac received FDA 510(k) clearance for pulmonary embolism treatment in fiscal 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAngioDynamics, Inc. (ANGO) - VRIO Analysis: 7. Established Global Regulatory and Reimbursement Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to secure FDA clearances and CPT codes streamlines market access and adoption globally. The NanoKnife System received CPT Category I codes for Irreversible Electroporation (IRE) in Prostate and Liver lesions, effective January 1, 2026, which facilitates reimbursement and broader access. The NanoKnife System also holds 510(k) clearance from the FDA for the surgical ablation of soft tissue.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While established medtech firms possess regulatory expertise, the recent achievement of CPT Category I status for a novel technology like IRE is a key differentiator. The company's total pro forma net sales for the year ended May 31, 2025, were $292.7 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Building regulatory expertise and relationships takes years, but the process itself is standardized. The company has been organized since 1992 and completed its initial public offering in 2004.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The speed at which they converted clinical trial success into reimbursement codes demonstrates strong organizational execution. For instance, the Med Tech segment, which includes NanoKnife, saw pro forma net sales growth of 19.5% for Fiscal Year 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Regulatory expertise is a necessary, ongoing capability that new entrants struggle to build quickly. AngioDynamics maintains dedicated reimbursement resources and guides for multiple product lines.\u003c\/p\u003e\n\u003cp\u003eKey statistical and financial data related to regulatory and market access:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Date\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanoKnife CPT Codes Effective Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 1, 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor Prostate and Liver IRE procedures.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Clearance (NanoKnife)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e510(k) Clearance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor surgical ablation of soft tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 Pro Forma Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$292.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended May 31, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2026 Q1 Pro Forma Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$75.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter ended August 31, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanoKnife Disposable Sales (Q3 FY25)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncreased 16.2% year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eGlobal regulatory approvals and key coding milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA 510(k) Clearance for NanoKnife System for surgical ablation of soft tissue.\u003c\/li\u003e\n\u003cli\u003eCommercialization approval in Canada, the European Union, and Australia for the NanoKnife System.\u003c\/li\u003e\n\u003cli\u003eReceipt of CPT Category I codes for IRE in the Prostate and Liver.\u003c\/li\u003e\n\u003cli\u003ePhysician Relative Value Units (RVUs) attached to new CPT codes effective January 1, 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAngioDynamics, Inc. (ANGO) - VRIO Analysis: 8. High Gross Margin Profile in Med Tech\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The Med Tech segment demonstrates a significantly superior margin profile compared to the Med Device segment, directly contributing to overall profitability.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eMed Tech Segment\u003c\/td\u003e\n\u003ctd\u003eMed Device Segment\u003c\/td\u003e\n\u003ctd\u003eOverall GAAP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (Q2 FY25)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e54.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Sales (Q2 FY25)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$31.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$41.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$73.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The high gross margin, even when facing headwinds, suggests underlying strength, though tariffs have caused temporary compression.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric (Q4 FY25)\u003c\/td\u003e\n\u003ctd\u003eReported Gross Margin\u003c\/td\u003e\n\u003ctd\u003eGross Margin Excluding Tariff Impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed Tech Segment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed Device Segment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Q2 FY25 Med Tech gross margin of \u003cstrong\u003e63.7%\u003c\/strong\u003e was an increase of 120 basis points from Q2 FY24, driven by growth in AngioVac. The Q4 FY25 Med Tech gross margin, absent tariff impacts, would have been \u003cstrong\u003e62.1%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The margin advantage is linked to proprietary platforms such as NanoKnife, AngioVac, and Auryon, which have regulatory milestones supporting their value.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNanoKnife System received CPT Category I Codes for Irreversible Electroporation (IRE) effective January 1, 2026.\u003c\/li\u003e\n\u003cli\u003eAngioVac and AlphaVac sales increased approximately 46% in Q4 FY25.\u003c\/li\u003e\n\u003cli\u003eAuryon sales increased 19.7% in Q4 FY25, reaching \u003cstrong\u003e$15.6 million\u003c\/strong\u003e for the quarter.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management has executed a strategic shift to prioritize and grow the higher-margin Med Tech portfolio.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMed Tech Net Sales grew \u003cstrong\u003e25.0%\u003c\/strong\u003e year-over-year in Q2 FY25.\u003c\/li\u003e\n\u003cli\u003eIn Q4 FY25, the Med Tech segment represented \u003cstrong\u003e45%\u003c\/strong\u003e of total revenue, up from 41% in the same quarter last year.\u003c\/li\u003e\n\u003cli\u003eThe company is transitioning to outsourced manufacturing, expected to yield \u003cstrong\u003e$15 million\u003c\/strong\u003e in annual savings by FY 2027.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The continued growth and premium pricing power of the Med Tech portfolio, evidenced by strong segment sales growth, support the persistence of this margin differential.\u003c\/p\u003e\n\u003cp\u003eFull Year FY25 Med Tech net sales were \u003cstrong\u003e$126.7 million\u003c\/strong\u003e, representing a \u003cstrong\u003e19.5%\u003c\/strong\u003e increase.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAngioDynamics, Inc. (ANGO) - VRIO Analysis: 9. Deep Specialization in Interventional Specialties\n\u003c\/h2\u003e\n\u003cp\u003eFinance: finalize the FY2026 capital expenditure plan based on the \u003cstrong\u003e$55.9 million\u003c\/strong\u003e cash balance by next Wednesday.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Focusing on interventional radiologists and vascular surgeons for niche, minimally invasive procedures ensures targeted sales and clinical support.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many large firms are broad; AngioDynamics’ deep focus on vascular and oncology intervention is a specialized strength.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Competitors can hire specialized sales reps, but building deep clinical trust takes time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Their entire commercial structure is aligned to serve these specific, high-value physician groups.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Specialized clinical knowledge and relationships are hard-won and difficult for generalist competitors to displace.\u003c\/p\u003e\n\u003cp\u003eThe specialization is evident in the performance of the Med Tech segment, which addresses an estimated \u003cstrong\u003e$10 billion\u003c\/strong\u003e in annual global market opportunities, up from \u003cstrong\u003e$3 billion\u003c\/strong\u003e in 2021.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecialized Product\/Area\u003c\/th\u003e\n\u003cth\u003eQ4 FY2025 Net Sales (USD)\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Growth\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed Tech Net Sales (Total)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$35.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuryon Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMechanical Thrombectomy Revenue (AngioVac\/AlphaVac)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e44.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanoKnife Disposable Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey financial metrics underscore the current operational context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash balance as of May 31, 2025: \u003cstrong\u003e$55.9M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY2025 Full Year Net Sales: \u003cstrong\u003e$292.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY2026 Projected Net Sales Range: \u003cstrong\u003e$308 million to $313 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY2026 Projected Adjusted Loss Per Share Range: \u003cstrong\u003e($0.35) to ($0.25)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ4 FY2025 Med Device Net Sales: \u003cstrong\u003e$44.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY2024 Pro Forma Net Sales: \u003cstrong\u003e$270.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516112822421,"sku":"ango-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ango-vrio-analysis.png?v=1740146489","url":"https:\/\/dcf-model.com\/pt\/products\/ango-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}